Jpmorgan Chase & CO Catalyst Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 374,373 shares of CPRX stock, worth $8.14 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
374,373
Previous 476,420
21.42%
Holding current value
$8.14 Million
Previous $7.59 Million
23.64%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CPRX
# of Institutions
299Shares Held
97.5MCall Options Held
29.2KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$407 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$199 Million2.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.1MShares$176 Million0.0% of portfolio
-
State Street Corp Boston, MA6.03MShares$131 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3MShares$65.3 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.24B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...